SESSION TYPE: Respiratory Infections Posters I
PRESENTED ON: Wednesday, October 24, 2012 at 01:30 PM - 02:30 PM
PURPOSE: To determine the incidence of MDR-TB among patients who received category II regimen at the Lung Center of the Philippines.
METHODS: Retrospective Chart Review
RESULTS: There were 363 patients who received category II treatment 16 (4.4%) patients had mono-resistance, 14 (3.9%) patients had Polyresistance, 129 (35.5%) were MDR-TB. 152 (41.9%) were culture negative and 52 (14.3%) were culture positive but fully susceptible. Of the 129 patients who developed MDR-TB, 58 (45%) belonged to the Category I failure group, 46 (33.3%) belonged to the Relapse group and 25 (27.5%) belonged to the RAD group.
CONCLUSIONS: The incidence of MDR-TB among patients who received category II treatment from December 2006 until December 2009 at the Lung Center of the Philippines was 35.5%. Of these, the highest was among Category I failure at 45%, followed by Relapse 35.6% and RAD at 19.4%.
CLINICAL IMPLICATIONS: We recommend that patients with category I failure should no longer receive category II treatment. Instead, MDR-TB screening should be done and standardized treatment for MDR-TB should be started. As for RAD, and Relapse, due to the high incidence of MDR-TB, MDR-TB screening should also be done and we need to carefully re-evaluate the use of Category II treatment regimen.
DISCLOSURE: The following authors have nothing to disclose: Augusto Sablan, Joven Gonong, Lawrence Raymond, Vivian Lofranco
No Product/Research Disclosure InformationLung Center of the Philippines, Quezon City, Philippines